Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Breast Neoplasms 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Recurrent Malignant Solid Neoplasm 1Non-hematologic Malignancy 1Neoplasms 1Multiple Myeloma 1Meningeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma, Large-Cell, Anaplastic 1Hematologic Neoplasms 1Gliosarcoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Nonhematological Neoplasms 1Adenoma, Islet Cell 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × sapanisertib × Clear all
NCT01118689 2013-08-02

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡